The guy at the end call saved us a little
desertfox398
Posts
-
-
I have never been in a stock and things went right
-
I can’t believe this smh you beat earnings and the stock goes down
-
Dumps all 27 contracts at Market good luck guys I’m out
-
Another day of BS
-
Trying HARD to uptrend right now if it does could hit .60 before close
-
Still uptrending just overbought at $3.65 don’t worry
-
Avg $1 a month movement
-
Who bought 100million at the beginning of June
-
Is earnings today or Aug 10?
-
TradingView says their earnings is tomorrow
-
Current position
-
You’re all fired...
-
Is earnings b4 or after the bell?
-
Winter is Coming
-
Glad my options are behind earnings (Aug 21)
-
So nothing??
-
Anything yet?
-
SAVA - Let's try this again? Presentation July 15 about SavaDx - Alzheimer's
DD
We have another Alzheimer's play here. Biogen (BIIB) submitted an Alzheimer's therapy to FDA for review on July 8 and its shares jumped 6%, but that's a higher-priced stock ($276) with a 162M float, compared to SAVA at 22M. Today INMB was up 120% on their Alzheimer's trial results.Back in May, the stock dropped from around $8 to $2.5 because of bad results from a drug study (https://www.streetinsider.com/dr/news.php?id=16890142). Now they're back with a blood-based diagnostic to detect Alzheimer’s disease (SavaDx), which they say on their website it has detected >10-fold differences between patients with Alzheimer’s and age-matched normal controls or young cognitively intact subjects. This clinical-stage program is funded by NIH as well.
Their lead neuroscientist, Lindsay H. Burns, PhD, will give a keynote presentation at the Biomarkers for Alzheimer’s Disease Summit, a virtual conference, on July 15, 2020. Dr. Burns’ talk will focus on SavaDx, the Company’s investigational diagnostic to detect Alzheimer’s disease with a simple blood test. https://finance.yahoo.com/news/cassava-sciences-keynote-presentation-savadx-200110208.html
The last time they gave a positive presentation, their stock shot up over 200% in a week https://www.nasdaq.com/articles/cassava-sciences-sava-is-up-200-in-6-days-whats-the-buzz-2019-12-30
From 3/26: Cassava Sciences is continuing the development of proprietary antibodies and other detection systems for use with SavaDx. Assuming technical success with on-going efforts, the Company expects to initiate a validation/disease specificity study with SavaDx in the second half of 2020. Cassava Sciences expects to present a technical update for SavaDx at a major scientific conference in 2020 (July 17)
HOME
HOME
HOME
SAVA
SAVA
SAVA
SAVA
SAVA
SAVA
SAVA
SAVA
SAVA
SAVA
SAVA
SAVA
SAVA
SAVA
SAVA
SAVA
SAVA